If you made any changes in Pure these will be visible here soon.

Personal profile


Dr Luc Furic is a Senior Research Fellow in the Department of Anatomy and Developmental Biology.

My current research program focuses on survival signalling in prostate cancer cells and its role in the transition from hormone-sensitive to castrate-resistant prostate cancer. My laboratory uses biochemical and molecular biology approaches to gain a better understanding of the molecular mechanisms responsible for prostate cancer initiation and progression.

Since 2002, I have received multiple scholarships, awards and fellowships from competitive schemes at both national and international levels. These awards include the US Department of Defense Postdoctoral Prostate Cancer training award (2009-2011), the Canadian Cancer Society Postdoctoral Fellowship (2008-2010), the Quebec Health Fund graduate scholarship (2003-2006) and postdoctoral fellowship (2007-2009), the National Science and Engineering Council of Canada graduate scholarship (2004-2006). More recently, I was awarded the ARC DECRA (2012-2015), a Young Investigator Award from the Prostate Cancer Foundation of Australia (2011-2016) and a Victorian Cancer Agency Early Career Seed grant (2011-2012).



  • Cancer Biology
  • Translation
  • Prostate Cancer
  • Signalling pathways

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2011 2021

Research Output 2002 2019

A balancing act: PHLPP2 fine tunes AKT activity and MYC stability in prostate cancer

Toivanen, R. & Furic, L., 3 Jun 2019, In : Journal of Cell Biology. 218, 6, p. 1771-1772 2 p.

Research output: Contribution to journalEditorialOtherpeer-review

Generally applicable transcriptome-wide analysis of translation using anota2seq

Oertlin, C., Lorent, J., Murie, C., Furic, L., Topisirovic, I. & Larsson, O., 9 Jul 2019, In : Nucleic Acids Research. 47, 12, 15 p., e70.

Research output: Contribution to journalArticleResearchpeer-review

Open Access

Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer

Watt, M. J., Clark, A. K., Selth, L. A., Haynes, V. R., Lister, N., Rebello, R., Porter, L. H., Niranjan, B., Whitby, S. T., Lo, J., Huang, C., Schittenhelm, R. B., Anderson, K. E., Furic, L., Wijayaratne, P. R., Matzaris, M., Montgomery, M. K., Papargiris, M., Norden, S., Febbraio, M. & 4 othersRisbridger, G. P., Frydenberg, M., Nomura, D. K. & Taylor, R. A., 6 Feb 2019, In : Science Translational Medicine. 11, 478, 12 p., eaau5758.

Research output: Contribution to journalArticleResearchpeer-review

V-ATPase-associated prorenin receptor is upregulated in prostate cancer after PTEN loss

Mohammad, A. H., Assadian, S., Couture, F., Lefebvre, K. J., El-Assaad, W., Barrs, V., Ouellet, V., Boulay, P. L., Yang, J., Latour, M., Furic, L., Muller, W., Sonenberg, N., Mes-Masson, A. M., Saad, F., Day, R. & Teodoro, J. G., 13 Aug 2019, In : Oncotarget. 10, 48, p. 4923-4936 14 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access

AMP-activated protein kinase selectively inhibited by the type II inhibitor SBI-0206965

Dite, T. A., Langendorf, C. G., Hoque, A., Galic, S., Rebello, R. J., Ovens, A. J., Lindqvist, L. M., Ngoei, K. R. W., Ling, N. X. Y., Furic, L., Kemp, B. E., Scott, J. W. & Oakhill, J. S., 1 Jan 2018, In : Journal of Biological Chemistry. 293, 23, p. 8874-8885 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access